Literature DB >> 17229142

Effect of oculopharyngeal muscular dystrophy-associated extension of seven alanines on the fibrillation properties of the N-terminal domain of PABPN1.

Grit Lodderstedt1, Simone Hess, Gerd Hause, Till Scheuermann, Thomas Scheibel, Elisabeth Schwarz.   

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant disease that usually manifests itself within the fifth decade. The most prominent symptoms are progressive ptosis, dysphagia, and proximal limb muscle weakness. The disorder is caused by trinucleotide (GCG) expansions in the N-terminal part of the poly(A)-binding protein 1 (PABPN1) that result in the extension of a 10-alanine segment by up to seven more alanines. In patients, biopsy material displays intranuclear inclusions consisting primarily of PABPN1. Poly l-alanine-dependent fibril formation was studied using the recombinant N-terminal domain of PABPN1. In the case of the protein fragment with the expanded poly l-alanine sequence [N-(+7)Ala], fibril formation could be induced by low amounts of fragmented fibrils serving as seeds. Besides homologous seeds, seeds derived from fibrils of the wild-type fragment (N-WT) also accelerated fibril formation of N-(+7)Ala in a concentration-dependent manner. Seed-induced fibrillation of N-WT was considerably slower than that of N-(+7)Ala. Using atomic force microscopy, differences in fibril morphologies between N-WT and N-(+7)Ala were detected. Furthermore, fibrils of N-WT showed a lower resistance against solubilization with the chaotropic agent guanidinium thiocyanate than those from N-(+7)Ala. Our data clearly reveal biophysical differences between fibrils of the two variants that are likely caused by divergent fibril structures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229142     DOI: 10.1111/j.1742-4658.2006.05595.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  7 in total

Review 1.  Oculopharyngeal muscular dystrophy: a polyalanine myopathy.

Authors:  Bernard Brais
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

Review 2.  PABPN1: molecular function and muscle disease.

Authors:  Ayan Banerjee; Luciano H Apponi; Grace K Pavlath; Anita H Corbett
Journal:  FEBS J       Date:  2013-05-24       Impact factor: 5.542

3.  A folded and functional protein domain in an amyloid-like fibril.

Authors:  Mirko Sackewitz; Sabrina von Einem; Gerd Hause; Michael Wunderlich; Franz-Xaver Schmid; Elisabeth Schwarz
Journal:  Protein Sci       Date:  2008-04-18       Impact factor: 6.725

4.  Conformational stability of the RNP domain controls fibril formation of PABPN1.

Authors:  Jens Liebold; Reno Winter; Ralph Golbik; Gerd Hause; Christoph Parthier; Elisabeth Schwarz
Journal:  Protein Sci       Date:  2015-08-27       Impact factor: 6.725

5.  Polyalanine-independent conformational conversion of nuclear poly(A)-binding protein 1 (PABPN1).

Authors:  Reno Winter; Uwe Kühn; Gerd Hause; Elisabeth Schwarz
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

6.  Influence of the stability of a fused protein and its distance to the amyloidogenic segment on fibril formation.

Authors:  Anja Buttstedt; Reno Winter; Mirko Sackewitz; Gerd Hause; Franz-Xaver Schmid; Elisabeth Schwarz
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

7.  Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy.

Authors:  Nicolas Barbezier; Aymeric Chartier; Yannick Bidet; Anja Buttstedt; Cécile Voisset; Hervé Galons; Marc Blondel; Elisabeth Schwarz; Martine Simonelig
Journal:  EMBO Mol Med       Date:  2011-01       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.